FAQ: Innovative MedTech's Rebranding to AnTix Holdings and Business Model Shift
Summary
Innovative MedTech has changed its name to AnTix Holdings and shifted its business focus from medical technology to online ticketing and entertainment technology, marking a significant corporate transformation aimed at growth in the AI-powered ticketing sector.
What is the main announcement in this press release?
Innovative MedTech has completed a corporate rebranding and name change to AnTix Holdings, Inc., and is shifting its business model from medical technology to the online ticketing and entertainment technology sector.
Why is the company changing its name and business focus?
The rebranding better aligns with the company’s new strategic direction of expanding into the growing online ticketing sector, where they see opportunities to apply artificial intelligence and Web 3.0 tools to improve the ticketing experience.
When did the name change officially take effect?
The company filed a Certificate of Amendment with the State of Delaware on September 19, 2025, to change its corporate name from ‘Innovative MedTech, Inc.’ to ‘AnTix Holdings, Inc.’
Who is leading this corporate transformation?
Michael J. Friedman, President and CEO of AnTix Holdings, Inc., is leading the transformation and announced the company’s new strategic direction.
What is the company’s new business focus and mission?
AnTix Holdings is now a technology company that delivers artificial intelligence to online ticketing, with a mission to bring transparency, efficiency and personalization to the ticketing and entertainment industry.
How does this change affect current stockholders?
The company’s common stock continues to trade under the ticker symbol ‘IMTH’ for now, and outstanding stock certificates remain valid without needing to be exchanged at this time.
What are the company’s growth plans in the new business sector?
The company plans to build value through innovation, execution and acquisition in the ticketing market, focusing on applying AI and Web 3.0 tools to improve the live experience for consumers and partners.
Does the company still have any medical technology business?
Yes, the company remains the exclusive licensor for the Oral Thrush application of Shear Kershman Labs’ BioViscid™ bio-adhesive encapsulation alongside its new ticketing technology business.
Where can I find more information about AnTix Holdings?
For more information, visit https://www.antixholdings.com
What is the current status of the company’s ticketing technology?
The company’s ticketing technology has already begun generating revenues and is expected to provide a strong foundation for the company’s next phase of growth.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at NewMediaWire
Article Control ID: 256776